DescriptionMember of New Drugs Committee of Scottish Medicines Consortium
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the status of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002). This advice will be made available as soon as practical after the launch of the product involved.
The remit of SMC excludes the assessment of vaccines, branded generics, non-prescription-only medicines (POMs), blood products, plasma substitutes and diagnostic drugs. The review of device-containing medicines will be confined to those licensed as medicines by the MHRA/EMEA.
SMC also has a horizon scanning function; the aim is to improve financial and service planning within NHS Boards through the provision of early intelligence on new medicines in development. An annual ‘Forward Look’ report is sent in strict confidence to key Health Board personnel.
The remit of SMC was further expanded from April 2008 to include the work of the Scottish Antimicrobial Prescribing Group. This group aims to co-ordinate and deliver a national framework for antimicrobial stewardship to enhance the quality of prescribing of antimicrobials across all healthcare settings. This will primarily be achieved through improved systems and processes for collation, analysis, correlation and reporting of antimicrobial utilisation and resistance data and improved education programmes for healthcare professionals.